PDE4B polymorphisms and decreased PDE4B expression are associated with schizophrenia

S H Fatemi; David P. King; Teri J. Reutiman; Timothy D. Folsom; Jessica A. Laurence; Susanne S Lee; Yu Ti Fan; Sara A. Paciga; Marco Conti; Frank S. Menniti

doi:10.1016/j.schres.2008.01.029

PDE4B polymorphisms and decreased PDE4B expression are associated with schizophrenia

S H Fatemi, David P. King, Teri J. Reutiman, Timothy D. Folsom, Jessica A. Laurence, Susanne S Lee, Yu Ti Fan, Sara A. Paciga, Marco Conti, Frank S. Menniti

Psychiatry & Behavioral Sciences

Research output: Contribution to journal › Article › peer-review

112 Scopus citations

Abstract

Schizophrenia has a complex genetic underpinning and variations in a number of candidate genes have been identified that confer risk of developing the disorder. We report in the present studies that several single nucleotide polymorphisms (SNPs) and a two-SNP haplotype in PDE4B are associated with an increased incidence of schizophrenia in two large populations of Caucasian and African American patients. The SNPs in PDE4B associated with schizophrenia occur in intronic sequences in the vicinity of a critical splice junction that gives rise to the expression of PDE4B isoforms with distinct regulation and function. We also observed specific decreases in phosphodiesterase 4B (PDE4B) isoforms in brain tissue obtained postmortem from patients diagnosed with schizophrenia and bipolar disorder. PDE4B metabolically inactivates the second messenger cAMP to regulate intracellular signaling in neurons throughout the brain. Thus, the present observations suggest that dysregulation of intracellular signaling mediated by PDE4B is a significant factor in the cause and expression, respectively, of schizophrenia and bipolar disorder and that targeting PDE4B-regulated signaling pathways may yield new therapies to treat the totality of these disorders.

Original language	English (US)
Pages (from-to)	36-49
Number of pages	14
Journal	Schizophrenia Research
Volume	101
Issue number	1-3
DOIs	https://doi.org/10.1016/j.schres.2008.01.029
State	Published - Apr 2008

Bibliographical note

Funding Information:
Funding for this study was provided by the Stanley Medical Research Institute (SMRI), Grant #06R-1406 (SHF). SMRI had no further role in study design; in the collection, analysis, and interpretation of data; in the writing of the report; and in the decision to submit the paper for publication.

Funding Information:
Grant support by the Stanley Medical Research Institute (Grant #06R-1406) to SHF is gratefully acknowledged. Postmortem brain tissue was donated by The Stanley Medical Research Institute's brain collection courtesy of Drs. Michael B. Knable, E. Fuller Torrey, Maree J. Webster, and Robert H. Yolken.

Copyright:
Copyright 2008 Elsevier B.V., All rights reserved.

Keywords

Bipolar disorder
Major depression
Phosphodiesterase 4B
Polymorphisms
Schizophrenia

Access

10.1016/j.schres.2008.01.029

OpenUrl availability

Full text

Cite this

@article{13be43cd040c413ebe147ce7829c3349,

title = "PDE4B polymorphisms and decreased PDE4B expression are associated with schizophrenia",

abstract = "Schizophrenia has a complex genetic underpinning and variations in a number of candidate genes have been identified that confer risk of developing the disorder. We report in the present studies that several single nucleotide polymorphisms (SNPs) and a two-SNP haplotype in PDE4B are associated with an increased incidence of schizophrenia in two large populations of Caucasian and African American patients. The SNPs in PDE4B associated with schizophrenia occur in intronic sequences in the vicinity of a critical splice junction that gives rise to the expression of PDE4B isoforms with distinct regulation and function. We also observed specific decreases in phosphodiesterase 4B (PDE4B) isoforms in brain tissue obtained postmortem from patients diagnosed with schizophrenia and bipolar disorder. PDE4B metabolically inactivates the second messenger cAMP to regulate intracellular signaling in neurons throughout the brain. Thus, the present observations suggest that dysregulation of intracellular signaling mediated by PDE4B is a significant factor in the cause and expression, respectively, of schizophrenia and bipolar disorder and that targeting PDE4B-regulated signaling pathways may yield new therapies to treat the totality of these disorders.",

keywords = "Bipolar disorder, Major depression, Phosphodiesterase 4B, Polymorphisms, Schizophrenia",

author = "Fatemi, {S H} and King, {David P.} and Reutiman, {Teri J.} and Folsom, {Timothy D.} and Laurence, {Jessica A.} and Lee, {Susanne S} and Fan, {Yu Ti} and Paciga, {Sara A.} and Marco Conti and Menniti, {Frank S.}",

note = "Funding Information: Funding for this study was provided by the Stanley Medical Research Institute (SMRI), Grant #06R-1406 (SHF). SMRI had no further role in study design; in the collection, analysis, and interpretation of data; in the writing of the report; and in the decision to submit the paper for publication. Funding Information: Grant support by the Stanley Medical Research Institute (Grant #06R-1406) to SHF is gratefully acknowledged. Postmortem brain tissue was donated by The Stanley Medical Research Institute's brain collection courtesy of Drs. Michael B. Knable, E. Fuller Torrey, Maree J. Webster, and Robert H. Yolken. Copyright: Copyright 2008 Elsevier B.V., All rights reserved.",

year = "2008",

month = apr,

doi = "10.1016/j.schres.2008.01.029",

language = "English (US)",

volume = "101",

pages = "36--49",

journal = "Schizophrenia Research",

issn = "0920-9964",

publisher = "Elsevier",

number = "1-3",

}

TY - JOUR

T1 - PDE4B polymorphisms and decreased PDE4B expression are associated with schizophrenia

AU - Fatemi, S H

AU - King, David P.

AU - Reutiman, Teri J.

AU - Folsom, Timothy D.

AU - Laurence, Jessica A.

AU - Lee, Susanne S

AU - Fan, Yu Ti

AU - Paciga, Sara A.

AU - Conti, Marco

AU - Menniti, Frank S.

N1 - Funding Information: Funding for this study was provided by the Stanley Medical Research Institute (SMRI), Grant #06R-1406 (SHF). SMRI had no further role in study design; in the collection, analysis, and interpretation of data; in the writing of the report; and in the decision to submit the paper for publication. Funding Information: Grant support by the Stanley Medical Research Institute (Grant #06R-1406) to SHF is gratefully acknowledged. Postmortem brain tissue was donated by The Stanley Medical Research Institute's brain collection courtesy of Drs. Michael B. Knable, E. Fuller Torrey, Maree J. Webster, and Robert H. Yolken. Copyright: Copyright 2008 Elsevier B.V., All rights reserved.

PY - 2008/4

Y1 - 2008/4

N2 - Schizophrenia has a complex genetic underpinning and variations in a number of candidate genes have been identified that confer risk of developing the disorder. We report in the present studies that several single nucleotide polymorphisms (SNPs) and a two-SNP haplotype in PDE4B are associated with an increased incidence of schizophrenia in two large populations of Caucasian and African American patients. The SNPs in PDE4B associated with schizophrenia occur in intronic sequences in the vicinity of a critical splice junction that gives rise to the expression of PDE4B isoforms with distinct regulation and function. We also observed specific decreases in phosphodiesterase 4B (PDE4B) isoforms in brain tissue obtained postmortem from patients diagnosed with schizophrenia and bipolar disorder. PDE4B metabolically inactivates the second messenger cAMP to regulate intracellular signaling in neurons throughout the brain. Thus, the present observations suggest that dysregulation of intracellular signaling mediated by PDE4B is a significant factor in the cause and expression, respectively, of schizophrenia and bipolar disorder and that targeting PDE4B-regulated signaling pathways may yield new therapies to treat the totality of these disorders.

AB - Schizophrenia has a complex genetic underpinning and variations in a number of candidate genes have been identified that confer risk of developing the disorder. We report in the present studies that several single nucleotide polymorphisms (SNPs) and a two-SNP haplotype in PDE4B are associated with an increased incidence of schizophrenia in two large populations of Caucasian and African American patients. The SNPs in PDE4B associated with schizophrenia occur in intronic sequences in the vicinity of a critical splice junction that gives rise to the expression of PDE4B isoforms with distinct regulation and function. We also observed specific decreases in phosphodiesterase 4B (PDE4B) isoforms in brain tissue obtained postmortem from patients diagnosed with schizophrenia and bipolar disorder. PDE4B metabolically inactivates the second messenger cAMP to regulate intracellular signaling in neurons throughout the brain. Thus, the present observations suggest that dysregulation of intracellular signaling mediated by PDE4B is a significant factor in the cause and expression, respectively, of schizophrenia and bipolar disorder and that targeting PDE4B-regulated signaling pathways may yield new therapies to treat the totality of these disorders.

KW - Bipolar disorder

KW - Major depression

KW - Phosphodiesterase 4B

KW - Polymorphisms

KW - Schizophrenia

UR - http://www.scopus.com/inward/record.url?scp=42749089914&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=42749089914&partnerID=8YFLogxK

U2 - 10.1016/j.schres.2008.01.029

DO - 10.1016/j.schres.2008.01.029

M3 - Article

C2 - 18394866

AN - SCOPUS:42749089914

SN - 0920-9964

VL - 101

SP - 36

EP - 49

JO - Schizophrenia Research

JF - Schizophrenia Research

IS - 1-3

ER -

PDE4B polymorphisms and decreased PDE4B expression are associated with schizophrenia

Abstract

Bibliographical note

Keywords

Access

OpenUrl availability

Other files and links

Fingerprint

Cite this